Accelerating Biomarker-Driven Drugs into Clinical Trials Whilst Strategising Your CDx Development, IVDR Compliance and Commercialisation Path to Improve Clinical Decision-Making and Patient Outcomes

The 13th Clinical Biomarkers and CDx Europe 2023 returns as the premier European forum for end-to-end discussions, actionable insights, and partnership development to guide biomarker discovery and companion diagnostics (CDx) development programmes as they progress toward commercialisation.

With two dedicated tracks on Biomarker Development and Drug-Dx Development and Commercialisation, this summit will be your ultimate guide to:

1) Understand European Biomarkers and CDx Development advancements in multiple disease areas in oncology and non-oncology indications
2) Discuss emerging functional assays and software technologies to advance and accelerate clinical and research programs aimed at personalising care for patients
3) Stay up to date with European specific regulatory, commercialisation and market access challenges and processes to successfully create your end-to-end biomarker and CDx strategy
4) Join forces to define a better framework for reimbursement of biomarkers that enable an equitable access to them for patients

Whether working in Oncology, NASH, Neuroscience, Inflammatory or cardiovascular diseases, come and join 250+ Clinical Biomarkers, Translational Medicine, Precision Medicine and Companion Diagnostics Directors, Heads and VPs together with biomarker and CDx solution providers, regulatory experts and notified bodies for a well-rounded, all stakeholders included learning and networking experience that you can’t afford to miss out.

26 Apr - 27 Apr 2023, 7:30 am - 5:00 pm

Go to Event Website
Ticket pricing starts from:
Conference - Vendor and Solution Provider Pricing: GBP 3199.00, Conference - Drug Developers and Academics: GBP 0.50